Radiopharmaceuticals for Cancer Diagnosis

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Medical Imaging and Theranostics".

Deadline for manuscript submissions: closed (28 June 2018) | Viewed by 21769

Special Issue Editors


E-Mail Website
Guest Editor
Department of Radiology and Biomedical Imaging, University of California, San Francisco 185 Berry Street, Suite 350, San Francisco, CA 94107, USA
Interests: nuclear-based molecular imaging techniques including PET, SPECT, and PET-MRI; image quantification; immunological-based imaging agents for diagnosis of infection and cancer; radiopharmaceuticals for cancer diagnosis and therapy; radiomics
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Vaccine Translational Research Branch/VRP/DAIDS, National Institute of Allergy and Infectious Diseases (NIH), 5601 Fishers Lane, Room 9B56, Rockville, MD 20892, USA
Interests: radiotracers; drug discovery; drug development; biomarkers; end point; therapeutic effect; drug efficacy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue, “Radiopharmaceuticals for Cancer Diagnosis”, will provide a timely update on radiopharmaceuticals for diagnosing and characterizing various cancers using positron emission tomography (PET) or single photon emission computed tomography (SPECT). These radiopharmaceuticals are molecular imaging tools that are critical to the diagnosis and staging of cancers, as well as in selecting patients for various therapies and monitoring their outcomes.

Significant advances in radiochemistry and radiopharmaceutical production have allowed for wider adoption of nuclear-based molecular imaging techniques, such as PET and SPECT. Recently, new cancer-targeting diagnostic and “theranostic” radiopharmaceuticals have become commercially available. There are several others in the regulatory approval pipeline.

This Special Issue will specifically explore novel radiopharmaceuticals for the diagnosis or characterization of various cancers, new applications for well-characterized radiopharmaceuticals, new radiochemistry methodologies, and novel strategies in quantitative molecular imaging of radiopharmaceuticals, as applied to cancer.

Submissions contributing to the understanding of the use of radiopharmaceuticals in the diagnosis or characterization of cancer, through basic science, pre-clinical, and clinical studies are cordially invited.

Both original manuscripts and reviews will be considered.

Prof. Dr. Benjamin Franc
Dr. Krishan Kumar
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Cancer imaging
  • Radiochemistry
  • Radiopharmaceuticals
  • Positron emission tomography (PET)
  • Single photon emission computed tomography (SPECT)
  • Theranostics
  • Immuno-PET
  • Antibody imaging

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

17 pages, 4678 KiB  
Review
Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer
by Nat P. Lenzo, Danielle Meyrick and J. Harvey Turner
Diagnostics 2018, 8(1), 16; https://doi.org/10.3390/diagnostics8010016 - 11 Feb 2018
Cited by 96 | Viewed by 20994
Abstract
Over 90% of prostate cancers over-express prostate specific membrane antigen (PSMA) and these tumor cells may be accurately targeted for diagnosis by 68Ga-PSMA-positron emission tomography/computed tomography (68Ga-PSMA-PET/CT) imaging. This novel molecular imaging modality appears clinically to have superseded CT, and [...] Read more.
Over 90% of prostate cancers over-express prostate specific membrane antigen (PSMA) and these tumor cells may be accurately targeted for diagnosis by 68Ga-PSMA-positron emission tomography/computed tomography (68Ga-PSMA-PET/CT) imaging. This novel molecular imaging modality appears clinically to have superseded CT, and appears superior to MR imaging, for the detection of metastatic disease. 68Ga-PSMA PET/CT has the ability to reliably stage prostate cancer at presentation and can help inform an optimal treatment approach. Novel diagnostic applications of 68Ga-PSMA PET/CT include guiding biopsy to improve sampling accuracy, and guiding surgery and radiotherapy. In addition to facilitating the management of metastatic castrate resistant prostate cancer (mCRPC), 68Ga-PSMA can select patients who may benefit from targeted systemic radionuclide therapy. 68Ga-PSMA is the diagnostic positron-emitting theranostic pair with the beta emitter Lutetium-177 PSMA (177Lu-PSMA) and alpha-emitter Actinium-225 PSMA (225Ac-PSMA) which can both be used to treat PSMA-avid metastases of prostate cancer in the molecular tumor-targeted approach of theranostic nuclear oncology. Full article
(This article belongs to the Special Issue Radiopharmaceuticals for Cancer Diagnosis)
Show Figures

Figure 1

Back to TopTop